Healthtech Investors & VC Firms in San Francisco
228 firms in this list, with a median first check of $500K. 80 of them lead rounds. Generated from verified public data and updated continuously.
SOSV
New YorkPre-Seed–Series B$30K – $550K
30 people
FTV Capital
New YorkSeries A–Growth$10M – $30M
17 people
Mana Ventures
EsteroSeed–Series A
6 people
Rising Tide
PacificaPre-Seed–Series B
19 people
Bay City Capital
San RafaelSeed–Late Stage$5M – $10M
8 people
Council
NashvilleGrowth$2M – $100M
21 people
Outsiders
NorwalkPre-Seed–Series B$500K – $8M
13 people
Alta Partners
JacksonSeed–Growth$1M – $12M
9 people
Dellin Investments
PhiladelphiaPre-Seed–Growth
7 people
Monograph Capital Partners
LondonSeed–Series B
23 people
415 Capital
MunichSeries A–Late Stage$5.4M – $16.2M
15 people
Z21 Ventures
San Francisco Bay AreaPre-Seed–Series A$500K – $1M
10 people
Big Pi Ventures
AthensPre-Seed–Growth$540K – $3.2M
17 people
Healthy Ventures
Mill ValleyPre-Seed–Series A$1M – $3M
11 people
One Planet Group
Walnut CreekPre-Seed–Late Stage
3 people
Shoreline Venture Management
San Francisco Bay AreaSeed–Growth$250K – $8M
11 people
11.2 Capital
Las VegasPre-Seed–Series B$500K – $3M
4 people
Foreground Capital
BostonPre-Seed–Series B
8 people
Magnetic Ventures
BostonSeed–Series A$1M – $6M
9 people
Accelerator Ventures
MiamiPre-Seed–Series B$2M
5 people
Creative Ventures
San Francisco Bay AreaPre-Seed–Series A$1M
4 people
Cherubic Ventures
Grand CaymanPre-Seed–Series A$220K – $27M
8 people
Bison Ventures
SeattleSeed–Series A
6 people
The Rise Fund
Fort WorthGrowth
11 people
Related lists
Investors & VC Firms in North America (14139)Investors & VC Firms in United States (13277)Investors & VC Firms in Europe (5574)Crypto & Web3 Investors & VC Firms (4829)Investors & VC Firms in Global (4159)SaaS Investors & VC Firms (3860)AI & Machine Learning Investors & VC Firms (3768)Fintech Investors & VC Firms (3725)Investors & VC Firms in Asia-Pacific (3573)Healthtech Investors & VC Firms (3414)
Data sourced from public filings and firms' own websites — see our methodology.





































































)
)
)


















